GlassScriptPhysician profile
Neil M Sullivan
NPI 1346215464
$1,764.40
in general payments reported to CMS, 2019-2025
8 companies · $530 in 2025
The $530 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $93.80 · 2021: $28.82 · 2022: $316 · 2023: $175 · 2024: $501 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.03 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $674.88 | 2020-2025 | Bimzelx, Cimzia |
| Amgen INC. | $352.85 | 2022-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $162.58 | 2019-2023 | |
| Lilly USA, LLC | $147.88 | 2023-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $141.02 | 2023-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $138.06 | 2024-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $124.93 | 2024 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $22.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.